



(11) **EP 1 551 372 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 54**

(51) Int Cl.:  
**A61K 9/14** <sup>(2006.01)</sup> **A61K 9/16** <sup>(2006.01)</sup>  
**A61K 9/20** <sup>(2006.01)</sup> **A61K 9/28** <sup>(2006.01)</sup>  
**A61K 9/50** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**01.08.2018 Bulletin 2018/31**

(86) International application number:  
**PCT/US2003/029475**

(45) Date of publication and mention  
of the grant of the patent:  
**06.06.2018 Bulletin 2018/23**

(87) International publication number:  
**WO 2004/026283 (01.04.2004 Gazette 2004/14)**

(21) Application number: **03752490.7**

(22) Date of filing: **22.09.2003**

(54) **SEQUESTERING SUBUNIT AND RELATED COMPOSITIONS AND METHODS**

SEQUESTRIER-UNTEREINHEIT UND RELEVANTE ZUSAMMENSETZUNGEN UND VERFAHREN  
SOUS-UNITE DE SEQUESTRATION ET COMPOSITIONS ET PROCEDES ASSOCIES

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PT RO SE SI SK TR**

(72) Inventor: **BOEHM, Garth**  
**Westfield, NJ 07090 (US)**

(30) Priority: **20.09.2002 US 412208 P**

(74) Representative: **Pfizer**  
**European Patent Department**  
**23-25 avenue du Docteur Lannelongue**  
**75668 Paris Cedex 14 (FR)**

(43) Date of publication of application:  
**13.07.2005 Bulletin 2005/28**

(56) References cited:  
**WO-A-01/58447 WO-A1-01/58451**  
**US-A- 5 639 476**

(60) Divisional application:  
**11005554.8 / 2 422 772**  
**11005555.5 / 2 422 773**  
**11005556.3 / 2 422 775**  
**17153385.4**

• "chapter <711>: Dissolution" In: "The United  
States Pharmacopeia, USP 26, NF21", 1 January  
2003 (2003-01-01)

(73) Proprietor: **Alpharma Pharmaceuticals LLC**  
**New York, NY 10017-5703 (US)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 551 372 B8**